Clinical trial endpoints for patients with gliomas-Reference-Cited by-同舟云学术

Clinical trial endpoints for patients with gliomas

Published:2017-02-14 Issue:4 Volume:4 Page:201-208
ISSN:2054-2577
Container-title:Neuro-Oncology Practice
language:en
Short-container-title:

Author:

Taylor Jennie W¹²,Molinaro Annette M¹³,Butowski Nicholas¹,Prados Michael¹

Affiliation:

1. Department of Neurological Surgery, University of California San Francisco, San Francisco, California (J.W.T., A.M.M., N.B., M.P.)

2. Department of Neurology, University of California San Francisco, San Francisco, California (J.W.T.)

3. Department of Epidemiology & Biostatistics, University of California at San Francisco, San Francisco, California (A.M.M.)

Abstract

Abstract Malignant glioma represents a diverse set of molecularly heterogeneous diseases. Few therapeutic agents have been approved despite decades of clinical trials research and pre-clinical investigation. Attempts to refine neuroimaging criteria and recent discovery of the genomic profiles linking tumor subsets to survival outcomes have spurred discussion on a variety of new approaches in clinical trial design and relevant endpoints. Here we focus on those endpoints in clinical trial design for patients with primary glioma and related issues still to be resolved.

Publisher

Oxford University Press (OUP)

Subject

Medicine (miscellaneous)

Link

http://academic.oup.com/nop/article-pdf/4/4/201/29005670/npw034.pdf

Reference45 articles.

1. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide;Polley;Neuro Oncol,2010

2. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group;Galanis;Lancet Oncol,2012

3. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme;Ballman;Neuro Oncol,2007

4. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas;Lamborn;Neuro Oncol,2008

5. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402;Cairncross;J Clin Oncol,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpoint;Contemporary Clinical Trials;2023-06

2. Initiatives Toward Clinical Boron Neutron Capture Therapy in Japan;Cancer Biotherapy and Radiopharmaceuticals;2023-04-01

3. Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma;Scientific Reports;2022-05-24

4. High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes;Expert Review of Anticancer Therapy;2022-02-13

5. Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial;Journal of Clinical Neuroscience;2021-12